Xenon Pharmaceuticals Inc.

Novartis Ag

Novartis Pharma Gmbh

Jianmin Fu

Shaoyi Sun

Sultan Chowdhury

Rajender Kamboj

Shifeng Liu

Serguei Sviridov

Zaihui Zhang

Mikhail A Chafeev

Vishnumurthy Kodumuru

Nagasree Chakka

Duanjie Hou

Jean-Jacques Alexandre Cadieux

Jianyu Sun

Vandna Raina

Qi Jia

Natalia Pokrovskaia

Natalie Alysia Dales

Tom Hsieh

Julia Fonarev

Alla Yurevna Zenova

Mark Wood

Jonathan David Langille

Lauren Fraser

Simon James Gauthier

Mehran Seid Bagherzadeh

Robert Fraser

Stefanie Abel

Emad El-Sayed

Elke Huthmann

Thomas Isarno

Amy Frances Douglas

Zoran Cikojevic

Mehran Bagherzadeh

Kashinath Sadalapure

Tarek Suhayl Mansour

Michael Edward Grimwood

Ivan William Hemeon

Shifeng Lui

Qi Ji

Mikhail Chafeev

Rajender K Kamboj

Jia Qi

This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Synthetic methods for spiro-oxindole compounds

This invention is directed to asymmetric syntheses of certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents

This invention is directed to the (S)-enantiomer of the compound of formula (I): or a pharmaceutically acceptable solvate or prodrug thereof. This (S)-enantiomer is useful for the treatment of diseases or conditions, such as pain, which are ameliorated or alleviated by the modulation of voltage-gated sodium channels.

Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents

This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Spiro-oxindole compounds and their use as therapeutic agents

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

Organic compounds

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I), where V, W, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R, R, R, R, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer. 

Use of spiro-oxindole compounds as therapeutic agents

Spiro-oxindole compounds and their uses as therapeutic agents

Growing community of inventors

Coquitlam, Canada

Jianmin Fu